{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:11:59Z","timestamp":1762607519930,"version":"3.41.2"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Natural Science Foundation of Hubei Province of China","award":["2015CFB708","2015CFC780"],"award-info":[{"award-number":["2015CFB708","2015CFC780"]}]},{"name":"Education Commission of Hubei Province of China","award":["D20152801","B2016194"],"award-info":[{"award-number":["D20152801","B2016194"]}]},{"name":"Innovative Training Program for National College Students","award":["201810927010"],"award-info":[{"award-number":["201810927010"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Archiv der Pharmazie"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A series of novel 1<jats:italic>H<\/jats:italic>\u20101,2,3\u2010triazole tethered isatin\u2013moxifloxacin (MXF) hybrids <jats:bold>5a<\/jats:bold>\u2010<jats:bold>l<\/jats:bold> with greater lipophilicity compared with the parent MXF were designed, synthesized and screened for their in vitro antimycobacterial activities against <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (MTB) H<jats:sub>37<\/jats:sub>Rv and multidrug\u2010resistant MTB (MDR\u2013MTB) as well as their cytotoxicity on the VERO cell line. All the synthesized hybrids (MIC: 0.025\u20100.78 \u03bcg\/ml) showed considerable activities against MTB H<jats:sub>37<\/jats:sub>Rv and MDR\u2013MTB, and the most active conjugate <jats:bold>5c<\/jats:bold> (MIC: 0.025 and 0.06 \u03bcg\/ml) was 2 to &gt;2048 times more potent in vitro than the three references MXF (MIC: 0.10 and 0.12 \u03bcg\/ml), rifampicin (MIC: 0.39 and 32 \u03bcg\/ml) and isoniazid (MIC: 0.05 and &gt;128 \u03bcg\/ml) against the two tested strains. All hybrids (CC<jats:sub>50<\/jats:sub>: 4\u201064 \u03bcg\/ml) were much more cytotoxic than the parent MXF (CC50: 128 \u03bcg\/ml), but the most active hybrid <jats:bold>5c<\/jats:bold> (CC<jats:sub>50<\/jats:sub>: 32 \u03bcg\/ml) also displayed acceptable cytotoxicity, warranting further investigation.<\/jats:p>","DOI":"10.1002\/ardp.201900040","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T08:50:39Z","timestamp":1558342239000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["1<i>H<\/i>\u20101,2,3\u2010Triazole tethered isatin\u2010moxifloxacin: Design, synthesis and in vitro anti\u2010mycobacterial evaluation"],"prefix":"10.1002","volume":"352","author":[{"given":"Yu","family":"Jiang","sequence":"first","affiliation":[{"name":"School of Nuclear Technology and Chemistry &amp; Biology Hubei University of Science and Technology Xianning Hubei People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailin","family":"Qian","sequence":"additional","affiliation":[{"name":"School of Nuclear Technology and Chemistry &amp; Biology Hubei University of Science and Technology Xianning Hubei People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0160-5007","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Nuclear Technology and Chemistry &amp; Biology Hubei University of Science and Technology Xianning Hubei People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"e_1_2_6_1_2_1","unstructured":"World Health Organization Global Tuberculosis Report 2018. (Report no. 1\u201014). World Health Organization: Geneva 2018."},{"key":"e_1_2_6_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2016.07.032"},{"key":"e_1_2_6_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.04.002"},{"key":"e_1_2_6_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.05.004"},{"key":"e_1_2_6_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.06.051"},{"key":"e_1_2_6_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(03)00208-7"},{"key":"e_1_2_6_1_8_1","unstructured":"Guidelines for the management of drug\u2010resistant tuberculosis(Report No. WHO\/TB\/96\u2010210; Rev.1). Geneva: World Health Organization1997."},{"key":"e_1_2_6_1_9_1","first-page":"61","volume":"28","author":"Feng L. S.","year":"2012","journal-title":"Chem. Res. Chin. Univ"},{"key":"e_1_2_6_1_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx150"},{"key":"e_1_2_6_1_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22071171"},{"key":"e_1_2_6_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.02.065"},{"key":"e_1_2_6_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2005.05.063"},{"key":"e_1_2_6_1_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000048533"},{"key":"e_1_2_6_1_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.661"},{"key":"e_1_2_6_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2010.11.023"},{"key":"e_1_2_6_1_17_1","first-page":"37","volume":"36","author":"Wan Z. L.","year":"2011","journal-title":"Chin. J. Antibiot"},{"key":"e_1_2_6_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.10.016"},{"key":"e_1_2_6_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.05.057"},{"key":"e_1_2_6_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2011.03.039"},{"key":"e_1_2_6_1_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja045147v"},{"key":"e_1_2_6_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2011.10.049"},{"key":"e_1_2_6_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2014.10.024"}],"container-title":["Archiv der Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fardp.201900040","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.201900040","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ardp.201900040","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.201900040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T01:45:35Z","timestamp":1694310335000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ardp.201900040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1002\/ardp.201900040"],"URL":"https:\/\/doi.org\/10.1002\/ardp.201900040","archive":["Portico"],"relation":{},"ISSN":["0365-6233","1521-4184"],"issn-type":[{"type":"print","value":"0365-6233"},{"type":"electronic","value":"1521-4184"}],"subject":[],"published":{"date-parts":[[2019,5,20]]},"assertion":[{"value":"2019-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1900040"}}